Global Conjugate Vaccine Market:
Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. The global conjugate vaccine market is expected to grow at a CAGR of 14.6%, leading to a global revenue of USD 100.59 Bn by 2023. By volume, it is anticipated to reach 9600.56 Million units by 2023, expanding at a CAGR of 17.2%.
The conjugate vaccine market is classified into two primary segments-based on disease indication: pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others; and based on end user: paediatric and adult. Asia-Pacific will have the highest CAGR during the forecasted period.
Key growth factors:
o Rising adoption of cancer therapeutic vaccines, improvement in patient compliance along with an increasing product pipeline, and growing efforts for the adoption of appropriate preventive screening methods to help avert adverse reactions will accelerate the market.
o Conjugate Vaccine market is expected to have positive growth owing to technological advancements, growth initiatives for the production of low-cost vaccines, and widespread routine vaccination programs in emerging economies.
Threats and key players:
o Although the conjugate vaccine market is expected to have a positive growth globally, lack of awareness, shortage risk, the situation of oligopoly, uncertainty about the future of international initiatives, emerging manufacturers, and costs and prices of new vaccines will hinder growth.
o Major Conjugate Vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Sanofi Pasteur, Novartis, etc.
What's covered in the report?
1. Overview of the global conjugate vaccine market
2. Market drivers and challenges in the global conjugate vaccine market
3. Market trends in the global conjugate vaccine market
4. Historical, current and forecasted market size data for the global disease indication segment (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) - by revenue and by volume
5. Historical, current and forecasted market size data for the global end user segment (paediatric and adult conjugate vaccines) - by revenue and by volume
6. Historical, current and forecasted regional (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) market size data for the conjugate vaccine market - by revenue and by volume
7. Historical, current and forecasted market size data for the region-wise conjugate vaccine market segments - by revenue and by volume
8. Analysis of the competitive landscape and profiles of major companies operating in the market
Why buy?
o Understand the demand for conjugate vaccines to determine the viability of the market
o Determine the developed and emerging markets where conjugate vaccines are provided
o Identify the challenge areas and address them
o Develop strategies based on the drivers, trends and highlights for each of the segments
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
o Recognize the key competitors of this market and respond accordingly
o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
o Define the competitive positioning by comparing the products and services with the key players in the market
Customizations available
With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.
Chapter 1: Executive summary
1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary - I
1.4 Executive summary - II
Chapter 2: Market overview
2.1. Market definitions
2.2. Global market overview - by revenue
- Global historical (2015-2017) market revenue (USD Bn)
- Global forecasted (2018-2023) market revenue (USD Bn)
- Geography-wise market (2018-2023) revenue (USD Bn)
2.3. Global market overview - by volume
- Global historical (2015-2017) market volume (Million units)
- Global forecasted (2018-2023) market volume (Million units)
- Geography-wise (2018-2023) market volume (Million units)
2.4. Global market drivers and challenges
2.4.1. Global market drivers
2.4.2. Global market challenges
2.5. Global market trends
2.6. Value chain
2.7.1. Regional market overview - North America
- Observation
- Key competitors
2.7.1(A) Regional market overview - North America by revenue and by volume
- North America historical (2015-2017) market revenue (USD Bn)
- North America forecasted (2018-2023) market revenue (USD Bn)
- North America historical (2015-2017) market volume (Million units)
- North America forecasted (2018-2023) market volume (Million units)
2.7.2. Regional market overview - Europe
- Observation
- Key competitors
2.7.2(A) Regional market overview - Europe by revenue and by volume
- Europe historical (2015-2017) market revenue (USD Bn)
- Europe forecasted (2018-2023) market revenue (USD Bn)
- Europe historical (2015-2017) market volume (Million units)
- Europe forecasted (2018-2023) market volume (Million units)
2.7.3. Regional market overview - Asia-Pacific
- Observation
- Key competitors
2.7.3(A) Regional market overview - Asia Pacific by revenue and by volume
- Asia Pacific historical (2015-2017) market revenue (USD Bn)
- Asia Pacific forecasted (2018-2023) market revenue (USD Bn)
- Asia Pacific historical (2015-2017) market volume (Million units)
- Asia Pacific forecasted (2018-2023) market volume (Million units)
2.7.4. Regional market overview - Latin America
- Observation
- Key competitors
2.7.4(A) Regional Market Overview - Latin America by revenue and by volume
- Latin America historical (2015-2017) market revenue (USD Bn)
- Latin America forecasted (2018-2023) market revenue (USD Bn)
- Latin America historical (2015-2017) market volume (Million units)
- Latin America forecasted (2018-2023) market volume (Million units)
2.7.5. Regional market overview - Middle East & Africa
- Observation
- Key competitors
2.7.5(A) Regional market overview - Middle East & Africa by revenue and by volume
- Middle East & Africa historical (2015-2017) market revenue (USD Bn)
- Middle East & Africa forecasted (2018-2023) market revenue (USD Bn)
- Middle East & Africa historical (2015-2017) market volume (Million units)
- Middle East & Africa forecasted (2018-2023) market volume (Million units)
Chapter 3: Major segment overview - global by disease indication
3.1. Disease indication: Pneumococcal, Hib - by revenue, by volume, CAGR
- Overview - by disease indication
- Market share (2015, 2018 & 2023): Pneumococcal - global revenue (USD Bn)
- Market share (2015, 2018 & 2023): Pneumococcal - global volume (Million units)
- Market share (2015, 2018 & 2023): Hib - global revenue (USD Bn)
- Market share (2015, 2018 & 2023): Hib - global volume (Million units)
3.2. Disease indication: DTP, Meningococcal - by revenue, by volume, CAGR
- Overview - by disease indication
- Market share (2015, 2018 & 2023): DTP - global revenue (USD Bn)
- Market share (2015, 2018 & 2023): DTP - global volume (Million units)
- Market share (2015, 2018 & 2023): Meningococcal - global revenue (USD Bn)
- Market share (2015, 2018 & 2023): Meningococcal - global volume (Million units)
Chapter 4: Major segment overview - global by end user
4.1. End-user: Pediatric, Adult - by revenue, by volume, CAGR
- Overview - by end user
- Market share (2015, 2018 & 2023): Paediatric - global revenue (USD Bn)
- Market share (2015, 2018 & 2023): Paediatric - global volume (Million units)
- Market share (2015, 2018 & 2023): Adult - global revenue (USD Bn)
- Market share (2015, 2018 & 2023): Adult - global volume (Million units)
Chapter 5: North America - by disease indication
5.1. North America: disease indication - Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.2. North America: disease indication - Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.3. North America: disease indication - Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
5.4. North America: disease indication - Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
Chapter 6: North America - by end user
6.1. North America: end user - Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
Chapter 7: Europe - by disease indication
7.1. Europe: disease indication - Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.2. Europe: disease indication - Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.3. Europe: disease indication - Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
7.4. Europe: disease indication - Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
Chapter 8: Europe - by end user
8.1. Europe: end user - Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
Chapter 9: Asia Pacific - by disease indication
9.1. Asia Pacific: disease indication - Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.2. Asia Pacific: disease indication - Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.3. Asia Pacific: disease indication - Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
9.4. Asia Pacific: disease indication - Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
Chapter 10: Asia Pacific - by end user
10.1. Asia Pacific: end user - Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
Chapter 11: Latin America - by disease indication
11.1. Latin America: disease indication - Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
11.2. Latin America: disease indication - Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
11.3. Latin America: disease indication - Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
11.4. Latin America: disease indication - Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
Chapter 12: Latin America - by end user
12.1. Latin America: end user - Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways
Chapter 13: Middle East & Africa - by disease indication
13.1. Middle East & Africa: disease indication - Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
13.2. Middle East & Africa: disease indication - Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
13.3. Middle East & Africa: disease indication - Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
13.4. Middle East & Africa: disease indication - Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
Chapter 14: Middle East & Africa - by end user
14.1. Middle East & Africa: end user - Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways
Chapter 15: Competitive landscape
15.1. Company market share
- Top 5 companies
15.2. Company overview - GlaxoSmithKline
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.2(A) Executive profile - GlaxoSmithKline
15.3. Company overview - Pfizer Inc.
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.3(A) Executive profile - Pfizer Inc.
15.4. Company overview - Merck & Co.
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.4(A) Executive profile - Merck & Co.
15.5. Company overview - Novartis
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.5(A) Executive profile - Novartis
15.6. Company overview - Sanofi Pasteur
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.6(A) Executive profile - Sanofi Pasteur
15.7. Company overview - CSL Limited
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.7(A) Executive profile - CSL Limited
15.8. Company overview - Bharat Biotech International
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.8(A) Executive profile - Bharat Biotech International
15.9. Company overview - Biological E Limited
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.9(A) Executive profile - Biological E Limited
15.10. Company overview - Serum Institute of India
- Company snapshot
- Product offerings
- Growth strategies
- Initiatives
- Geographical presence
15.10(A) Executive profile - Serum Institute of India
Appendix
- List of tables
- Assumptions
- Conclusion
- Research and methodology
- About Netscribes Inc.
Request Sample 
Request Discount 
Inquire Before Buy
